IGM Biosciences Inc. (IGMS) Reports Q4 Loss of $0.79/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 4:17 PM EDTRecommended Phase 2 Dose for IGM-2323 Expected in 2021
Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021
IND Filing for IGM-7354 Planned in 2021
Company to Host Conference Call Today at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent... More
